Thromboprophylaxis
We recommend
Biosimilars in the Prophylaxis of Venous Thromboembolism
Nízkomolekulární hepariny jsou zlatým standardem antitrombotické profylaxe u chirurgických i interních pacientů. Od roku 2016 je v EU registrován první biosimilární enoxaparin – Inhixa. Italská studie přináší výsledky hodnocení jeho účinnosti a bezpečnosti v prevenci žilní tromboembolie v reálné klinické praxi i jejich porovnání se sdruženými daty u srovnatelné populace pacientů z klinických studií s originálním enoxaparinem.
Potential of Enoxaparin to Maintain A-V Shunt Patency According to the SEP Protocol
A newly published study by authors from Singapore focused on the ability of the SEP protocol –…
How to Navigate the Challenges of Anticoagulant Therapy in Pregnant Women − A Case Study
Every carrier of a mechanical heart valve is also on anticoagulant therapy. Warfarin is most…
Articles on this topic
Thromboprophylaxis as a Common Part of Care for At-Risk Patients Requiring Hospitalization: Yes or No?
The proportion of patients requiring hospitalization who are at high risk of developing…
Thromboprophylaxis in Generalized Pancreatic Cancer
Pancreatic adenocarcinoma is one of the tumors with the highest risk of developing…
Extended Thromboprophylaxis with Enoxaparin After Bariatric Surgery
A recent retrospective study involving 312 patients after bariatric surgery indicated that…
Perioperative Thromboprophylaxis in Elderly Patients
Thromboembolic disease (TED) is among the most common causes of death in hospitalized patients…
Thromboprophylaxis with Enoxaparin Reduces Mortality in Patients Hospitalized with COVID-19
Severe acute respiratory syndrome caused by COVID-19 is associated with a hypercoagulable…
How to Prevent and Treat Thromboembolic Disease in Cancer Patients
Malignancy is one of the risk factors for the development of thromboembolic disease (TED).…
Different doses of LMWH in hospitalized patients with COVID-19 – interim experience
Many experts recommend administering heparin to patients with COVID-19 as part of…
Enoxaparin in Weight-Based Dosing for Thromboprophylaxis in Hospitalized Cancer Patients
Cancer patients are at higher risk of developing thromboembolic disease during…
Mass in the Left Atrium Appendage - Case Report
A symptomatic mass in the left atrial appendage warrants thorough investigation and radical…
Comparison of the Efficacy and Safety of Two Enoxaparin Dosing Regimens in Patients After Chest Surgery
Effective prevention of thromboembolic disease in patients undergoing chest surgery is one of…
Subscribe
Most read on this topic
Journal on this topic
Related topic
Most read on this topic
- Different doses of LMWH in hospitalized patients with COVID-19 – interim experience
- Low-Molecular-Weight Heparins in Thromboprophylaxis After Major Orthopedic and Traumatological Procedures According to Current Recommendations
- How to Manage Thromboprophylaxis in Obese and Extremely Obese Patients?
- Anticoagulants and Antiplatelets in the Treatment of Acute Coronary Syndromes
- Administration of Low-Molecular-Weight Heparin After Hemorrhagic Stroke: What Is the Appropriate Timing?
- Thromboprophylaxis with Enoxaparin Reduces Mortality in Patients Hospitalized with COVID-19
Journal on this topic
Related topic